All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), ipilimumab alone vs. ..., meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.82 [1.39; 2.38]
CheckMate 069 (all population), 2015 (REV) 1.35 [0.79; 2.31]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.69 [0.22; 2.17]
1.50 [1.02 ; 2.21 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 3 38% 804 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.92 [1.56; 2.37]
1.92 [1.56 ; 2.37 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 629 NA not evaluable PFS (extension)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.97; 2.87]
CheckMate 069 (all population), 2015 (REV) 2.78 [1.74; 4.43]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.14 [0.44; 10.39]
2.43 [2.04 ; 2.89 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 3 0% 804 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.76; 3.23]
CheckMate 069 (all population), 2015 (REV) 2.63 [1.59; 4.36]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.63 [1.02; 6.79]
CheckMate 069 (BRAF wild type), 2015 (REV) 2.50 [1.45; 4.30]
2.47 [1.96 ; 3.10 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV) 4 0% 913 low not evaluable objective responses (ORR)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.10; 0.28]
CheckMate 069 (all population), 2015 (REV) 0.07 [0.04; 0.12]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.21]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29]
0.10 [0.06 ; 0.18 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV) 4 39% 913 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.11; 0.23]
CheckMate 069 (all population), 2015 (REV) 0.08 [0.03; 0.23]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.20]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29]
0.14 [0.10 ; 0.19 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV) 4 0% 913 low not evaluable TRAE (any grade)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.27 [0.14; 0.51]
CheckMate 069 (all population), 2015 (REV) 1.33 [0.34; 5.28]
0.53 [0.11 ; 2.50 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 76% 764 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.26 [0.19; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.26 [0.12; 0.58]
0.26 [0.19 ; 0.36 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.17; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.10; 0.57]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.30 [0.12; 0.71]
0.25 [0.18 ; 0.35 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV) 3 0% 872 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.37 [0.25; 0.55]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.09; 0.63]
0.35 [0.24 ; 0.50 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 4.16 [0.14; 126.20]
2.57 [0.36 ; 18.33 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 4.23 [0.37; 47.88]
0.79 [0.03 ; 18.93 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 74% 764 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.56 [0.05 ; 6.42 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
2.03 [0.26 ; 15.80 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
2.05 [0.04 ; 105.24 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.92 [0.52; 1.65]
CheckMate 069 (all population), 2015 (REV) 0.34 [0.09; 1.23]
0.67 [0.27 ; 1.67 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 48% 764 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
1.02 [0.03 ; 31.03 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.03; 2.24]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.41 [0.06 ; 2.80 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.60 [0.33; 1.11]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.33; 3.19]
0.68 [0.40 ; 1.16 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.24 [0.03 ; 1.97 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.81 [0.15; 4.34]
0.81 [0.15 ; 4.34 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.22 [0.06; 0.80]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
0.22 [0.07 ; 0.70 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.45 [0.16; 1.29]
0.45 [0.16 ; 1.29 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.51 [0.02; 11.44]
0.50 [0.07 ; 3.38 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.01; 1.82]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.18 [0.02 ; 1.45 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.06 [0.00; 1.08]
0.06 [0.00 ; 1.08 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.42 [0.04 ; 4.55 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.29; 3.51]
CheckMate 069 (all population), 2015 (REV) 2.09 [0.29; 15.34]
1.24 [0.43 ; 3.57 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.92 [0.07 ; 12.01 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.02; 0.43]
CheckMate 069 (all population), 2015 (REV) 0.14 [0.01; 2.46]
0.11 [0.03 ; 0.39 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.07; 0.46]
CheckMate 069 (all population), 2015 (REV) 0.09 [0.01; 1.62]
0.16 [0.06 ; 0.41 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.17; 0.65]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.03; 1.97]
0.32 [0.17 ; 0.61 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.21 [0.04 ; 1.18 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
0.92 [0.07 ; 12.01 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.28 [0.06; 1.37]
CheckMate 069 (all population), 2015 (REV) 2.07 [0.13; 33.80]
0.54 [0.09 ; 3.35 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 32% 764 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.03; 3.22]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.09; 11.57]
0.56 [0.11 ; 2.95 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
1.44 [0.09 ; 23.12 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
0.27 [0.05 ; 1.66 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
0.43 [0.07 ; 2.81 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.17; 1.47]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
0.44 [0.16 ; 1.22 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
1.02 [0.03 ; 31.03 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.67 [0.07; 6.66]
0.67 [0.07 ; 6.66 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.10 [0.01; 1.83]
0.10 [0.01 ; 1.83 ] CheckMate 069 (all population), 2015 (REV) 1 0% 140 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.50 [0.02 ; 15.03 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
1.44 [0.09 ; 23.12 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.14 [0.02; 1.15]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
0.24 [0.04 ; 1.45 ] CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 2 0% 764 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CheckMate 067 (NI vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-05 19:06 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 329,558
